Manufacture and Sale of Medicines
Chong Kun Dang Pharmaceutical Corp. is one of leading Korean pharmaceutical manufacturers and has a great strength on domestic sales not only with prescription drugs indicated for anti-hypertension, anti-hyperlipidemia and anti-diabetics—such as Telminuvo®, Lipilou®, and Duvie®—as well as over-the-counter (OTC) and consumer health products, including insecticides and hair dyes.

Global Business Presence
Chong Kun Dang is expanding the market in worldwide with strategic products in immunosuppressants, anti-cancers and antibiotics. In order to grow strength in Glocalization (Globalization + Localization), Chong Kun Dang opened representative office in Vietnam since 2012 and established Joint Venture company in Indonesia in 2015.

Licensing and Tech Transfer
Chong Kun Dang is focused on in-licensing novel drugs which offers better solution for chronic disorders such as diabetes and cardiovascular diseases, as well as for anti-cancer therapies and neurological diseases with high medical unmet needs. Having developed Duvie®, the new drug for type II diabetes, Chong Kun Dang is actively expanding its global presence with the best-in-class anti-cancer pipelines (CKD-516 and CKD-581) and dyslipidemia therapy, starting from the neighboring Asian markets. Further, Chong Kun Dang has an in-house technology platform for HDAC6-selective inhibitors which provides the novel mechanism of action.We are enthusiastically preparing for the global market entry via strategic business diversification, specificallytargeting auto-immune diseases, neurological disorders, and cancer.

Business Alliance
Supported by its long presence in Korean pharmaceutical industry and strong sales and marketing capacity, Chong Kun Dang is involved in numerous business alliance relationships with the most prestigious multinational companies in various fields. Over the last decade, Chong Kun Dang has formed the partnership with MNCs such as Bayer, Roche, Allergan, Pfizer, and MSD and Amgen and, as a result, Chong Kun Dang has an unrivaled leadership in the local market enhanced by its robust product portfolio which now covers a broad range of therapeutic classes with innovative, outstanding drugs. Chong Kun Dang will continue to work towards mutual development through global business partnering.